乳腺癌
医学
平足蛋白
癌相关成纤维细胞
内科学
肿瘤科
癌症
荟萃分析
转移
癌症研究
免疫组织化学
作者
Meimei Cui,Hao Dong,Wanli Duan,Xuejie Wang,Yongping Liu,Lihong Shi,Baogang Zhang
出处
期刊:PeerJ
[PeerJ, Inc.]
日期:2024-02-23
卷期号:12: e16958-e16958
被引量:5
摘要
Background To elucidate the relationship between cancer-associated fibroblast (CAFs) biomarkers and the prognosis of breast cancer patients for individualized CAFs-targeting treatment. Methodology PubMed, Web of Science, Cochrane, and Embase databases were searched for CAFs-related studies of breast cancer patients from their inception to September, 2023. Meta-analysis was performed using R 4.2.2 software. Sensitivity analyses were performed to explore the sources of heterogeneity. Funnel plot and Egger’s test were used to assess the publication bias. Results Twenty-seven studies including 6,830 patients were selected. Univariate analysis showed that high expression of platelet-derived growth factor receptor- β (PDGFR- β ) ( P = 0.0055), tissue inhibitor of metalloproteinase-2 (TIMP-2) ( P < 0.0001), matrix metalloproteinase (MMP) 9 ( P < 0.0001), MMP 11 ( P < 0.0001) and MMP 13 ( P = 0.0009) in CAFs were correlated with reduced recurrence-free survival (RFS)/disease-free survival (DFS)/metastasis-free survival (MFS)/event-free survival (EFS) respectively. Multivariate analysis showed that high expression of α -smooth muscle actin ( α -SMA) ( P = 0.0002), podoplanin (PDPN) ( P = 0.0008), and PDGFR- β ( P = 0.0470) in CAFs was associated with reduced RFS/DFS/MFS/EFS respectively. Furthermore, PDPN and PDGFR- β expression in CAFs of poorly differentiated breast cancer patients were higher than that of patients with relatively better differentiated breast cancer. In addition, there is a positive correlation between the expression of PDPN and human epidermal growth factor receptor-2 (HER-2). Conclusions The high expression of α -SMA, PDPN, PDGFR- β in CAFs leads to worse clinical outcomes in breast cancer, indicating their roles as prognostic biomarkers and potential therapeutic targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI